Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

By J. Apperley. The Lancet Oncology, 2007

643 citations recorded by the source corpus.

Subfields: Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/1f1cf880b93b931c03e82e0b9a62075338a44d27

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. K. Borden
2. H. Zahreddine
3. J. Cortes
4. J. Apperley
5. Andreas Hochhaus
6. J. Goldman
7. H. Kantarjian
8. M. Baccarani

In Rheumatology

1. K. Borden
2. H. Zahreddine
3. J. Cortes
4. Andreas Hochhaus
5. H. Kantarjian
6. M. Baccarani
7. Brian J. Druker

Citations in the corpus

• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, methodology): “*Representative of the 10 most frequent mutations.(56,59) BLOOD, 8 AUGUST 2013 x VOLUME 122, NUMBER 6 ELN RECOMMENDATIONS FOR CML 875”
• Mechanisms and insights into drug resistance in cancer (2013, background): “Apperley, J. F. (2007). Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.”
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009, neutral): “Other methods can identify specific mutations with a much higher sensitivity, but it is believed that the detection of a small, mutated clone is not clinically relevant.(5,9,10,14,53,63,84) The development of new mutations is a recognized cause of resistance also to second-generation TKIs.”